TY - JOUR
T1 - Intrathecal baclofen for progressive neurological disease in childhood: A systematic review of literature
AU - Bonouvrie, Laura A.
AU - van Schie, Petra E. M.
AU - Becher, Jules G.
AU - van Ouwerkerk, Willem J. R.
AU - Vermeulen, R. Jeroen
PY - 2012
Y1 - 2012
N2 - Background: Intrathecal baclofen (ITB) treatment is frequently used for individuals with severe, but non-progressive, spasticity refractory to oral treatment. However, experiences with ITB in patients with progressive neurological disorders of childhood causing spasticity are limited. Aim: To investigate whether ITB is an option in patients with progressive neurological disorders causing spasticity in childhood. Design: A systematic literature search in Embase, Pubmed and the Cochrane Library was performed. Results: We identified six eligible studies considering patients with progressive neurological disease in childhood and receiving ITB treatment. The studies included a total of seven paediatric patients and four adult patients. Improvement was reported in spasticity, spasms, pain, gait, activities of daily life and providing care. High satisfaction is described. Conclusions: ITB has beneficial effects in paediatric patients with progressive neurological disease. However, the level of evidence is limited due to the small number of available studies and due to the poor quality of these studies. (C) 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved
AB - Background: Intrathecal baclofen (ITB) treatment is frequently used for individuals with severe, but non-progressive, spasticity refractory to oral treatment. However, experiences with ITB in patients with progressive neurological disorders of childhood causing spasticity are limited. Aim: To investigate whether ITB is an option in patients with progressive neurological disorders causing spasticity in childhood. Design: A systematic literature search in Embase, Pubmed and the Cochrane Library was performed. Results: We identified six eligible studies considering patients with progressive neurological disease in childhood and receiving ITB treatment. The studies included a total of seven paediatric patients and four adult patients. Improvement was reported in spasticity, spasms, pain, gait, activities of daily life and providing care. High satisfaction is described. Conclusions: ITB has beneficial effects in paediatric patients with progressive neurological disease. However, the level of evidence is limited due to the small number of available studies and due to the poor quality of these studies. (C) 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved
U2 - https://doi.org/10.1016/j.ejpn.2011.07.008
DO - https://doi.org/10.1016/j.ejpn.2011.07.008
M3 - Review article
C2 - 22015172
SN - 1090-3798
VL - 16
SP - 279
EP - 284
JO - European journal of paediatric neurology : EJPN
JF - European journal of paediatric neurology : EJPN
IS - 3
ER -